Pacira Biosciences, Inc. · NASDAQ:PCRX
Pacira Biosciences — Q2 2024 Earnings Presentation
18 slides from Pacira Biosciences's earnings presentation, Jul 30, 2024
Slide 1: Pacira BioSciences 2Q24 Earnings Presentation
Pacira BioSciences 2Q24 Earnings Presentation July 2024
Slide 2: Forward-looking statements and where to find additional information
Forward-looking statements and where to find additional information Any statements in this presentation about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “int
Slide 3: 1H24 marked by strong execution and meaningful progress
1H24 marked by strong execution and meaningful progress towards commercial, clinical and business objectives A A A A A Solid sales across Strengthened Leadership team Reshaped New talent & all 3 products balance sheet realignment corporate culture expertise across critical functions Foundation for m
Slide 4: Advancing three key EXPAREL drivers in 2024
Advancing three key EXPAREL drivers in 2024 Expanding Market preparation Broadening utilization of for Medicare’s patient access to EXPAREL as a lower implementation of EXPAREL through extremity nerve separate outpatient new GPO block reimbursement at partnerships ASP +6% 4
Slide 5: Lower extremity nerve block launch continues receiving positive market receptivity
Lower extremity nerve block launch continues receiving positive market receptivity across all sites of care • Extends reach within surgeries of the knee, lower leg, EXPAREL is and foot and ankle APPROVED for use in lower extremity procedures as an adductor – Strong presence in TKA; anticipate faster
Slide 6: NOPAIN-readiness activities to maximize reimbursement opportunity
NOPAIN-readiness activities to maximize reimbursement opportunity Advancing multiple initiatives to drive AWARENESS EDUCATION ACTION Pharmacy C-suite Clinicians Payers Influencers Patients 6
Slide 7: Generating real-world evidence to highlight opioid-sparing and economic benefits of EXPAREL
Generating real-world evidence to highlight opioid-sparing and economic benefits of EXPAREL Surgery Open Science The Spine Journal PRS Global Open Surgery Open Science The Spine Journal PRS Global Open Colorectal resection Outpatient spine Abdominal flap breast n=8,794 n=1,524 n=1,017 EXPAREL cohort
Slide 8: Launch of national campaign | Make the NOPAIN PACT
Launch of national campaign | Make the NOPAIN PACT A hand holding a cell phone Description automatically generated NOPAIN ACT campaign targets hospital Revenue Pharmacists Administrators Clinicians Management Teams to ensure these critical groups are up-to-speed and ready when new outpatient Medicar
Slide 9: Paving the way for separate EXPAREL reimbursement
Paving the way for separate EXPAREL reimbursement • Launching new GPO partnerships in 2024 ~25% of EXPAREL-relevant market procedures are in – In 1Q24, announced deal with Premier whose network of hospitals and health systems covers ~20% of EXPAREL-relevant market procedures inpatient – Premier part
Slide 10: PCRX-201 leverages properties of a novel High-Capacity Adenovirus platform
PCRX-201 leverages properties of a novel High-Capacity Adenovirus platform • High-Capacity Adenovirus (HCAd) platform offers Our strategy will unlock potential to address unmet needs in nongenetic, potential of gene therapy prevalent diseases like OA to provide meaningful, durable & economically via
Slide 11: High need for novel OA of the knee treatments given lack of durable efficacy
High need for novel OA of the knee treatments given lack of durable efficacy in current therapies 14M Americans suffer from symptomatic knee OA 2M younger than 45 3-6 limitation on durability of currently MONTH available treatments 11
Slide 12: PCRX-201 has the potential to be an important disease-modifying gene therapy for OA of the knee
PCRX-201 has the potential to be an important disease-modifying gene therapy for osteoarthritis (OA) of the knee +12 • 1-year Phase 1 data presented at OARSI 2024 and ASGCT 2024 – a single IA MONTHS injection: DURABILITY considered – Sustained clinically meaningful effect at all dose levels, across
Slide 13: Defending our intellectual property and the proven safety and integrity of EXPAREL
Defending our intellectual property and the proven safety and integrity of EXPAREL FDA’s recent generic EXPAREL approval has NO impact on our multiple patent infringement lawsuits against eVenus 1 Pacira wins lawsuit • Court enjoins eVenus from launching until ‘495 patent expires in Jan 2041 against
Slide 14: Strong balance sheet and significantly cash flow positive
Strong balance sheet and significantly cash flow positive • 2Q24 total revenue of $178M 2024 Financial Guidance Reiterated as of 2Q24 – EXPAREL net product sales of $137M Total Revenue $680-705M – ZILRETTA net product sales of $31M Non-GAAP Gross Margin 74-76% – iovera° net product sales of $6M Non-
Slide 15: Well-positioned for sustainable success
Well-positioned for sustainable success Sharply focused on driving long-term growth 3 best-in-class products LENB launch receiving positive market receptivity Significant reimbursement opportunity ahead 2024 a key setup year to drive growth in 2025 and beyond Advancing potentially transformative gen
Slide 16: Appendix
APPENDIX PACIRA BIOSCcIENC Ne
Slide 17: Non-GAAP disclosure
Non-GAAP disclosure Pacira BioSciences, Inc. Reconciliation of GAAP Net Income to Adjusted EBITDA (Non-GAAP) (in thousands) (unaudited) Three Months Ended June 30, 2024 GAAP net income $ 18,886 Interest income (4,749) Interest expense (1) 3,884 Income tax expense 17,698 Depreciation expense 4,541 Am
Slide 18: Thank you
BIOSCIENCES INC. Thank you